|Over a week ago|
Molecular Partners initiated with an Outperform at Cowen » 16:0207/1207/12/21
Cowen analyst Ken…
Cowen analyst Ken Cacciatore initiated coverage of Molecular Partners with an Outperform rating and $50 price target.
Molecular Partners price target lowered to CHF 26 from CHF 28 at RBC Capital » 11:1707/1207/12/21
RBC Capital analyst…
RBC Capital analyst Charles Weston lowered the firm's price target on Molecular Partners to CHF 26 from CHF 28 and keeps an Outperform rating on the shares.
Molecular Partners assumed with an Outperform at SVB Leerink » 07:4107/1207/12/21
SVB Leerink analyst Daina…
SVB Leerink analyst Daina Graybosch assumed coverage of Molecular Partners (MOLN) with an Outperform rating and $36 price target, from CHF35, and no longer will cover the Swiss shares. This half of the year, the analyst is focused on interim data from the Phase 2/3 EMPATHY study of ensovibep in ambulatory COVID-19, which could potentially support emergency use authorization and lead to an opt-in by partner Novartis (NVS) that would trigger a $164M or $5 per Molecular Partners share licensing fee for the latter. Beyond that, Graybosch looks for Phase 1 data from the immuno-oncology DARPins MP-0310/AMG-506, MP-0317 and their tetra-specific T cell engager for acute myeloid leukemia.
Molecular Partners provides update on clinical progress of ensovibep » 05:2607/0807/08/21
Molecular Partners (MOLN)…
Molecular Partners (MOLN) reported on the clinical progress of its novel antiviral candidate, ensovibep, as part of a presentation with its partner Novartis at the 1st Credit Suisse ESG Forum Switzerland virtual event. Ensovibep is designed to bind and inhibit SARS-CoV-2, the virus that causes COVID-19. Ensovibep is currently being studied in a Phase 2 single-arm pilot study in ambulatory patients in the Netherlands; a global Phase 2/3 study in ambulatory patients, conducted in collaboration with Novartis (NVS) and a National Institutes of Health, or NIH-sponsored global Phase 3 study in hospitalized patients as part of the ACTIV-3 master protocol. During the presentation, management outlined initiation of a subcutaneous program to align with the global registrational studies presently underway using administration via infusion. Initiating this year, the studies will evaluate ensovibep delivered subcutaneously to healthy individuals and subsequently to COVID-19 patients. Subcutaneous administration may increase ease and speed of administration to complement ensovibep's simple, high yield manufacturing process, stability, and potential inhibition of all major viral variants to-date. The EMPATHY study is presently enrolling across 5 countries, with continued expansion expected into additional territories as the evolving pandemic dictates. The ACTIV-3 study is presently enrolling patients in the hospitalized setting for assessment with ensovibep across more than 50 centers in 4 countries. The ACTIV-3 study protocol is open for recruitment in the hospitalized setting across 120 centers presently with more centers to open in the coming months. The program is aimed to be active in countries where the virus has high case numbers and to cover emerging variants on a global level. Finally, and in parallel to the clinical progress updated, ensovibep continues to be evaluated for its potency and inhibition against all emerging and established variants of concern. These evaluations are conducted across multiple laboratories, including the NIH. In vitro data to date show that ensovibep retains full potency and viral inhibition against all known SARS-CoV-2 variants in circulation, including the key Delta variants containing the T478K and K417N mutations, presently a particular concern as it may be associated with higher infectivity rates, even in individuals who are vaccinated.
|Over a month ago|
Molecular Partners assumed with a Buy at H.C. Wainwright » 06:1106/2106/21/21
H.C. Wainwright analyst…
H.C. Wainwright analyst Robert Burns assumed coverage of Molecular Partners with a Buy rating and $25 price target. The analyst says the company's "burgeoning early-stage oncology pipeline provides meaningful upside." He views Molecular's earlier-stage oncology portfolio as a potential driver of future upside.
Opening Day: WalkMe stock price falls following $287M IPO » 08:3406/1906/19/21
CYT, FEMY, AMAM, DNAY, TRMR, ATAI, IPSC, RERE, VERV, LYEL, ISPC, WKME, MOLN, CNVY, ALZN, FLYW, PAY, ZIP, DAWN, FIGS, OMIC, CNTA, DIDI, QNIU, RGCB, ELEV, CMSL, DNUT, YOU, GS, MS, JPM, AMZN, F, SAFO, HOOD
Backed by Insight Venture…
Molecular Partners opens at $20, IPO priced at $21.25 per ADS » 11:1706/1606/16/21
Molecular Partners (MOLN)…
Molecular Partners (MOLN) priced 3M American Depositary Shares at $21.25. Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.
Molecular Partners indicated to open at $20, IPO priced at $21.25 » 10:5106/1606/16/21
Molecular Partners (MOLN)…
Molecular Partners (MOLN) priced 3M American Depositary Shares at $21.25. JPMorgan, SVB Leerink and Cowen acted as joint book running managers for the offering. Molecular Partners is a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutics.
Molecular Partners 3M share IPO priced at $21.25 » 06:2006/1606/16/21
JPMorgan, SVB Leerink and…
JPMorgan, SVB Leerink and Cowen acted as joint book running managers for the offering.